巩固英股“第一大权重股”地位，医药巨头阿斯利康股价创新高

Core Viewpoint - AstraZeneca's stock price reached a historic high of £134.6, with a market capitalization nearing £210 billion ($282 billion), solidifying its position as the largest weight in the FTSE 100 index [1]. Group 1: Stock Performance - AstraZeneca's strong performance significantly boosted the FTSE 100 index, which rose by 1.1% to also reach a historic high, driven by improved UK employment data and expectations of interest rate cuts by the central bank [2]. - The stock price increase of AstraZeneca by 2.5% during intraday trading reflects investor confidence and market optimism [1]. Group 2: Financial Results - The recent stock surge is primarily supported by AstraZeneca's better-than-expected earnings report, which showed an 11% year-over-year increase in total revenue for the first three quarters, and a 15% growth in core earnings per share [4]. - All business segments and major regional markets of AstraZeneca demonstrated robust growth, indicating a strong operational performance [4]. Group 3: Market Environment - The recent agreement on drug pricing in the U.S. has alleviated market concerns regarding uncertainties in U.S. pharmaceutical policies, providing additional support for AstraZeneca's stock price [4]. - The U.S. market, contributing over 40% of AstraZeneca's total sales, plays a crucial role in the company's revenue generation and stock performance [4].